First FDA filing for Novartis’ latecomer PD-1 drug tislelizumabNovartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier Share XFirst FDA filing for Novartis’ latecomer PD-1 drug tislelizumabhttps://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/
ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence dataAstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in Share XASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence datahttps://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/
FDA fast-tracks Leap’s gastric cancer immunotherapyLeap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric Share XFDA fast-tracks Leap’s gastric cancer immunotherapyhttps://pharmaphorum.com/news/fda-fast-tracks-leaps-gastric-cancer-immunotherapy/
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese marketBoehringer Ingelheim is to manufacture the first biologic drug approved in China using a new regulatory system, designed Share XBoehringer cleared to manufacture BeiGene’s cancer drug for Chinese markethttps://pharmaphorum.com/news/boehringer-gets-clearance-to-manufacture/
BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WMBeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white Share XBeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WMhttps://pharmaphorum.com/news/beigenes-brukinsa-fails-to-beat-abbvie-jjs-ibrutinib-in-wm/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
Amgen pays $2.7bn to harness BeiGene’s China marketing muscleFuelled by sweeping regulatory reforms and a massive ageing population, China is a key market for most big Share XAmgen pays $2.7bn to harness BeiGene’s China marketing musclehttps://pharmaphorum.com/news/amgen-pays-2-7bn-to-harness-beigenes-china-marketing-muscle/
China’s BeiGene delays US filing for rival to ImbruvicaBeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s Share XChina’s BeiGene delays US filing for rival to Imbruvicahttps://pharmaphorum.com/news/chinas-beigene-delays-us-filing-for-rival-to-imbruvica/
